These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17939395)

  • 1. [Adaptive designs for clinical trial].
    Li W; He SJ; Wang Y; Cheng XR; Jia X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jun; 28(6):605-7. PubMed ID: 17939395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial designs--made to order.
    Andersen JS
    J Biopharm Stat; 1996 Nov; 6(4):515-22. PubMed ID: 8969983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.
    Sagkriotis A; Scholpp J
    Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential and adaptive designs: a novel, promising tool for nursing research.
    Baldi I; Gouchon SM; Di Giulio P; Buja A; Gregori D
    J Adv Nurs; 2011 Aug; 67(8):1824-33. PubMed ID: 21517937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group sequential and adaptive designs - a review of basic concepts and points of discussion.
    Vandemeulebroecke M
    Biom J; 2008 Aug; 50(4):541-57. PubMed ID: 18663761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive trial design: a general methodology for censored time to event data.
    Jahn-Eimermacher A; Ingel K
    Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.